Mako said last week that the offering, priced at $13.15 per share for more than 3 million shares, would go toward "commercialization infrastructure" and to cover other corporate expenses.
The company said at the time that the funding rounds could reach $43 million total if underwriter Piper Jaffray exercised a 456,000-share over-allotment, which it did.
The net proceeds of the offering, which closed on schedule on Nov. 19, amounted to $43 million after deducting underwriting discounts, commissions and estimated offering expenses, according to a press release.
MAKO shares were up 0.9% to $14.13 as of about 9:45 a.m. this morning.
On June 4-5, DeviceTalks Minnesota is taking over the Twin Cities medtech industry with one of the most anticipated conferences of the spring.
Join leaders from 3M, Abbott, Bigfoot Biomedical, Boston Scientific, Cardionomic, CMF Solutions, Cyient, Google Mayo Clinic, Medical Alley, Medtronic, NxThera, Opus College, Relievant Medsystems, University of Minnesota, Star Tribune, Smith & Nephew, Spry Health, Zimmer Biomet and many more when you register today.
Use the code "DTWeb" to save 15% on the cost of registration.